"We Envision Growth Strategies Most Suited
to Your Business"

Nuclear Medicine Market to Record 19.5% CAGR from 2023 to 2030; GE Healthcare Expands Portfolio with Acquisition of Zionexa and FDA Approval of Cerianna for Metastatic Breast Cancer

August 09, 2023 | Healthcare

The global nuclear medicine market size was valued at USD 7.53 billion in 2022. The market is projected to grow from USD 8.42 billion in 2023 to USD 29.35 billion by 2030, exhibiting a CAGR of 19.5% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Nuclear Medicine Market Size, Share & COVID-19 Impact Analysis, By Type (Diagnostic and Therapeutic), By Application (Neurology, Cardiology, Oncology, and Others), By End-user (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2023-2030”.


The market has witnessed significant growth due to the increasing prevalence of chronic diseases and advancements in radiopharmaceutical therapies. Nuclear medicine or radiopharmaceutical therapies have proven to be efficient in various clinical areas such as neurology, cardiology, and oncology. Market players are also driving growth through strategies such as new product launches and acquisitions, as seen with Life Healthcare's acquisition of TheraMed Nuclear's non-clinical imaging operations in South Africa.


Pandemic Impacted Market with the Decreased Imaging Procedures and Supply Chain Disruptions


The market faced challenges in 2020 due to the COVID-19 pandemic, including a decrease in imaging procedures and disruptions in the supply chain. The implementation of safety precautions and logistical challenges posed difficulties for centers. For example, there was a significant reduction in therapies, such as radioiodine therapy for thyroid cancer and benign diseases. Complete and partial lockdowns and restrictions on air travel impacted the distribution of radiopharmaceuticals to hospitals.


Telix Pharmaceuticals Collaborates with Heidelberg University Hospital to Develop Theranostic Compound for Urologic Oncology


In February 2023, Telix Pharmaceuticals Limited announced the successful completion of a research project in collaboration with Heidelberg University Hospital. The project focused on developing a theranostic compound for urologic oncology that targets PSMA and utilizes the beta-emitting isotope rhenium-188 (188Re). The aim of the project was to create and validate this compound as a potential treatment option.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/industry-reports/nuclear-medicine-radiopharmaceuticals-market-101812


Innovative Diagnostic Radiopharmaceuticals Address Rising Demand for Nuclear Imaging


The nuclear medicine market growth is driven by the introduction of new products by various market players. The rising demand for nuclear imaging and the prevalence of chronic diseases have led to the development of robust diagnostic radiopharmaceutical pipelines. For example, in March 2021, GE Healthcare launched StarGuide, a nuclear medicine system aimed at improving patient outcomes in various medical specialties such as bone procedures, neurology, cardiology, and oncology.


However, the market’s growth may face limitations due to the increasing use of alternative diagnostic imaging modalities such as CT and MRI.


Key Players Strategies for Success Include Innovation, Acquisitions, and Strong R&D Focus


The global market is predominantly controlled by key players who utilize strategies such as introducing new products, acquiring other companies, and investing in research and development to gain strong regulatory approvals. Additionally, there are other companies with significant market shares and robust pipelines of therapeutic radiopharmaceuticals that are poised to drive the market's growth in the future.


Key Industry Development



  • May 2021: GE Healthcare announced the acquisition of Zionexa to develop and bring to market Zionexa’s pipeline biomarkers that enabled more targeted treatment for metastatic breast cancer. Besides, recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), a molecular imaging agent to help inform treatment selection for metastatic breast cancer.


List of Companies Profiled in the Market Report:



  • Lantheus Medical Imaging, Inc. (U.S.)

  • Cardinal Health (U.S.)

  • Norgine B.V. (Netherlands)

  • Nordion (Canada) Inc. (Canada)

  • Bayer AG (Germany)

  • Curium (France)

  • Advanced Accelerator Applications (Novartis AG) (France)

  • Bracco Diagnostic Inc. (U.S.)

  • Jubilant Pharmova Limited (India)

  • GE Healthcare (General Electric Company) (U.S.)


Further Report Findings:



  • North America holds the largest nuclear medicine market share, driven by the widespread adoption of advanced imaging technologies and efficient therapeutic radiopharmaceuticals.

  • Europe is projected to be the second-largest market, supported by the adoption of advanced radiopharmaceuticals and strategic acquisitions.

  • The market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, with diagnostic radiopharmaceuticals leading the market in 2020 and expected to grow significantly.

  • The oncology segment is anticipated to experience the highest growth rate, fueled by the increasing prevalence of cancer and the development of pipeline products for nuclear medicine therapies in oncology.

  • Hospitals and clinics are expected to drive significant market growth due to their expertise in handling nuclear medicine products and high procedural volumes.


Table of Segmentation


























































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 19.5% from 2023-2030



Unit



Value (USD billion)



Segmentation



By Type, By Application, By End-user, and By Region



By Type




  • Diagnostic

    • PET Radiopharmaceuticals





  • FDG-PET/18F

  • 68Ga

  • 68Cu

  • 11C

  • Others





    • SPECT Radiopharmaceuticals





  • Technetium-99m

  • Iodine-123

  • Xenon-133

  • Thallium-201

  • Others



  • Therapeutic



By Application




  • Neurology

  • Cardiology

  • Oncology

  • Others



By End-user




  • Hospitals & Clinics

  • Diagnostic Centers

  • Others



By Region




  • North America (By Type, By Application, By End-user, By Country/ Sub-Region)

    • U.S.

    • Canada



  • Europe (By Type, By Application, By End-user, By Country/ Sub-Region)

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe



  • Asia Pacific (By Type, By Application, By End-user, By Country/ Sub-Region)

    • Japan

    • China

    • India

    • Australia

    • Rest of Asia Pacific



  • Rest of the World (By Type, By Application, By End-user, By Country/ Sub-Region)


Nuclear Medicine/ Radiopharmaceuticals Market
  • PDF
  • 2022
  • 2019-2021
  • 169

    CHOOSE LICENSE TYPE

  • 4850
    5850
    6850

Our Clients

Panasonic
Google
Ipsos
Kpmg
Citibank
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X